Latest From MorphoSys AG
The Munich-based company is one of a handful of mature European biotechs poised to enter the big league. New CEO Jean-Paul Kress talks to In Vivo about the firm’s next generation antibody platform and why US expansion is crucial to its future.
Analysts tip Munich-based company for greatness, but it will need a big pharma partner to take on Roche's Polivy in competitive hemato-oncology market.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.
The Japanese biotech agreed a multi-year, multi-target research collaboration and license deal with Takeda to discover and develop medicines that modulate GPCR targets, initially in GI.
Drug Discovery Tools
- Molecular Diversity
- Drug Discovery Tools
- In Vitro Diagnostics
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Immune Disorders
- Musculoskeletal & Connective Tissue Disorders
- Neurology, Nervous System
- Respiratory, Pulmonary
- Western Europe
- Parent & Subsidiaries
- MorphoSys AG
- Senior Management
Simon E Moroney, PhD, CEO
Jens Holstein, CFO
Malte Peters, MD, Chief Dev. Officer
Markus Enzelberger , PhD, CSO
- Contact Info
Phone: (49) 89 899 27 0
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.